Since our first report on the metabolic stimulant action of 2-4 dinitrophenol (alpha)1 in animals and men, and a preliminary paper indicating clinical possibilities for this compound,2 its use has been continued in the outpatient department of the Stanford Clinics and in private practice. Some of the early clinical results in obesity were summarized in a progress report.3 Various clinical reports have detailed the actions of the drug under different dietary conditions,4 its circulatory effects,5 changes in blood cholesterol,6 and effects on the icteric index and van den Bergh test.7 The evidences for changes in blood cholesterol, liver damage and certain red blood cell characteristics were negative. Our experimental work and clinical experience with the drug has now extended over a period of four years, during which time it has been given to hundreds of patients. Therefore it is felt that there may
TAINTER ML, STOCKTON AB, CUTTING WC. DINITROPHENOL IN THE TREATMENT OF OBESITY: FINAL REPORT. JAMA. 1935;105(5):332–337. doi:10.1001/jama.1935.02760310006002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: